EQUASENS: H1 2022 Results
Villers-lès-Nancy, 22 September 2022 - 6:00 p.m. (CET)
PRESS RELEASE
H1 2022
Results
-
Continuing growth:
- Revenue:
+10.30% to €103.57m
- Current
Operating Income: +5.37% to €25.76m
- Net Profit:
+18.92% to €20.95m
-
Group targets for H2 maintained, particularly for
earnings.
In
€m |
H1 2020 |
H1 2021 |
H1 2022 |
Change2022/2020 |
Change2022/2021 |
Revenue |
77.93 |
93.90 |
103.57 |
+ 32.90 % |
+ 10.30 % |
Current Operating
Income |
20.74 |
24.45 |
25.76 |
+ 24.25 % |
+ 5.37 % ** |
Net
Profit |
13.50 |
17.62 |
20.95 * |
+ 55.26 % |
+ 18.92 % |
Net Profit
attributable to owners of the Company |
12.63 |
16.59 |
19.73 |
+ 56.19 % |
+ 18.96 % |
Basic earnings
per share (in € - Attributable to owners of the Company) |
0.84 |
1.10 |
1.31 |
+ 56.67 % |
+ 19.10 % |
* Impact IP BOX option
+ financial returns
** Impact of higher
overhead costs vs. H1 2021
-
The Group is continuing to roll out
pandaLAB Pro, its secure
health messaging system which benefits patients by
improving the coordination of care between healthcare providers and
the public health system.
-
Update on
Ségur1
listings:
- MédiStory
4 (MEDICAL SOFT Division) is the first application
for primary care physicians to be qualified.
- DOMILINK
HAD, MEDILINK, HOSPILINK, TITAN: in the Hospital,
Primary Care Providers and Social Care categories within the
AXIGATE LINK Division, Equasens is the only group with a triple
certification.
- The
id. by Pharmagest - DOMILINK SSIAD
and TITANLINK solutions
for the Pharmacy and Social Care categories are currently being
examined by the French Digital Health Agency
(Agence du Numérique en Santé or
ANS).
The financial
statements for the six-month period ended 30 June 2022 were
reviewed and adopted by EQUASENS' Board of Directors, chaired by
Thierry CHAPUSOT, on 22 September 2022. These interim consolidated
financial statements were subject to a limited review by the
Statutory Auditors.
********
Equasens Group
recorded 10.30% growth in revenue for the six months ended
June 30, 2022, to €103.57m compared to H1 2021.
Like-for-like, revenue rose 7.68% to €101.11m, confirming the
positive impact of PROKOV EDITIONS’ acquisition in Q4 2021.
The Group's
Current Operating Income rose 5.37% to
€25.76m at June 30, 2022, largely in
response to the increase in non-recurring overhead costs from one
year earlier. For the 2022 full-year, the current operating margin
is expected to follow the same trends as in previous years.
- Current
Operating Income for the PHARMAGEST Division amounted to €17.05m
(+0.86%). The Division remains solidly on track, supported
by a very strong acceleration in business volume for the electronic
label offering in France and significant growth in recurring
revenues in Italy reflecting the contributions from new pharmacy
installations completed in 2021.
- Current
Operating Income for the AXIGATE
LINK
Division amounted to
€4.64m (+6.42%). Driven
by strong business momentum, all activities are progressing. In
parallel with the roll-out of its "new" solutions, both in the
social care (TITANLINK, DOMILINK - HAD and SSIAD, HOSPILINK,
MEDILINK) and in telemedicine (ETPLINK, CARELIB EHPAD and eNephro),
the Division is continuing to market pandaLAB Pro to improve the
coordination of patient care, and is planning the first deployments
of INFILINK, a fully mobile solution for private practice
nurses.
- Current
Operating Income of the Other Divisions (E-CONNECT
+ MEDICAL SOFT + FINTECH) of €4.08m
(+27.97%). Excluding FINTECH, whose sector has
been adversely affected by adverse market conditions, profitability
of E-CONNECT and MEDICAL SOFT Divisions remained on track.
Net Profit on
that basis amounted to €20.95m (+18.92%) and Net
Profit Attributable to Owners of the
Company to €19.73m (+18.96%). At 30 June
2022, Basic Earnings per Share amounted to
€1.31, up from € 1.10 one year
earlier
(+19.10%).
- Consolidated balance sheet highlights
At 30 June 2022,
Equasens Group's gross cash position increased to €121.74m, of from
€107.87m at 31 December 2021.
With a net cash
position (net of all loans) of €45.45m, Equasens Group maintains a
high degree of autonomy and a significant investment capacity to
take advantage of future acquisition opportunities.
Equity attributable to
owners of the Company at 30 June 2022 amounted to €161.78m.
- H1 2022 operating highlights
Dominique PAUTRAT, having
stepped down as Chief Executive Officer of Equasens Group to become
Chairman of the Board of Directors of La Coopérative WELCOOP,
parent company of Equasens Group, as of April 22, 2022,
Denis SUPPLISSON was appointed Chief Executive
Officer in his place as from 23 April 2022. Grégoire de
ROTALIER, appointed in July 2020, remains Deputy CEO,
while continuing to develop the AXIGATE LINK Division he manages,
and contributes to Equasens Group's cross-corporate projects.
The Extraordinary General Meeting of the
Shareholders held on 6 May at the company's headquarters adopted
the resolution to change the company’s name to
EQUASENS.This new name highlights the
interoperability of solutions developed for patients and healthcare
professionals and healthcare establishments while reinforcing the
Group's "Patient-Centred” positioning initiated over 10 years
ago:
- EQUA refers to
equation, and by extension the Group’s scientific origins,
technology;
- SENS emphasizes
the underlying meaning of its core mission: providing the right
information, to the right caregiver, at the right time for the
right patient.
This new name thus provides a perfect fit with
the Group's tagline “Technology for a more
human experience”.
“This change in name from Pharmagest to Equasens
better reflects the Group's new identity in terms of the diversity
of its activities and new markets. Today, our Group is no longer
solely a software developer for pharmacies but is also a leading
provider of healthcare solutions in Europe. For more than 10 years
now, we have expanded our positioning focused on the pharmacy
market to a provider of IT solutions to all healthcare
professionals in France and tomorrow in Europe” declared Thierry
CHAPUSOT, Chairman of the Board of Directors of the Equasens
Group.
- Update on listings with the
French digital healthcare sector programme
(Ségur du Numérique en
Santé)
- MédiStory
4 was the first medical practice management software to be
granted a Ségur listing number for the Primary Care Physician
category. PROKOV EDITIONS (MEDICAL SOFT Division) is the publisher
of this application, the market leader for Apple operating system
environments for over 30 years. MédiStory 4, the latest version of
the software, released 4 years ago, is equipped with all the Ségur
functionalities. The 155 functional requirements were fully
integrated into the software, without compromising the fluidity and
ergonomics so important for healthcare professionals used to our
software. This version was rolled out to users in June 2022.
- In the Hospital,
Primary Care Physicians and Social Care categories within the
AXIGATE LINK Division, Equasens is the only group having received a
triple certification.
- The
DOMILINK HAD solution obtained 3 unique Ségur
listing numbers for the 3 Software Specification Requirements (DSR
or Dossier de Spécifications de Référencement) of the Hospital
category: Electronic Health Record, Intermediation Platform and
Patient ID Application. With the DOMILINK range, DICSIT
INFORMATIQUE is the hospital-at-home care (HaH) leader with an
installed base of 160 establishments. These listings represent
the culmination of an entire year of development work focused on
integrating and optimizing Ségur functionalities; participating in
Task Forces to exchange views with industry stakeholders and
identify current obstacles to deploying core services (DMP, MSS,
etc.) and highlight the commitment of DICSIT INFORMATIQUE's
research and development and engineering teams.
- The
HOSPILINK software offering, developed by the
AXIGATE teams, obtained the Ségur listing under the EHR (Electronic
Health Record) qualification procedure in the Hospital category
with the following 3 profiles: Hospital - EHR: General /Hospital -
EHR: Patient Health ID integration / Hospital - EHR: Web client
EMR. During its review of the HOSPILINK application, the
French Digital Health Agency certification board assessed the
software's compliance with the required technical, functional and
ergonomic requirements and noted that "the management of data and
compliance with the procedures of the core services (were) carried
out within an application framework which provides reasonable
guarantees with respect to compliance with the specifications and
compliance scenarios as issued".
- ICT SOLUTIONS was
granted a Ségur listing for its MEDILINK software,
dedicated to medical practices and coordinated healthcare practice
(multidisciplinary group practices, territorial health professional
communities, etc.), for all specialties and organizations (primary
care physicians and specialists, midwifes, nurses,
physiotherapists, pharmacists, chiropodists, speech therapists,
orthoptists, dental surgeons, psychologists, medical social
workers), meeting the requirements of the supervisory authorities.
Available on both Windows and Apple operating systems, MEDILINK is
also available as an app and add-on module, MEDILINK App, for
tablets and smartphones providing access to key patient data and
calendars.
- Most recently, the
TITAN solution obtained a Ségur listing for its
“Electronic User File”. MALTA INFORMATIQUE is thus the first
software publisher in the nursing home sector to be granted this
listing. With an installed base of nearly 3,000 establishments
managing nearly 240,000 patients on a daily basis, the TITAN
application modeless all patient care processes in a single
database. Comprised of many application building blocks, this
software suite provides an effective and differentiating solution
within the evolving health and social care landscape.
- The id. by
Pharmagest - DOMILINK SSIAD and TITANLINK
solutions of interest for the Pharmacy and Social Care categories
were submitted to the French Digital Health Agency (ANS) and are
currently under review.
- Significant events occurring after 30 June
2022
- Equasens Group completes
the majority acquisitions of three companies
Therapeutic compliance is a key issue at the
European level in the management of elderly and chronically ill
patients. In 2022, continuing to implement a strategy focused on
patients and effective medication compliance, the Group has
increased its shareholdings in three of its European
subsidiaries:
- MULTIMEDS, an Irish
company which produces and distributes manual pill dispensers;
- CAREMEDS, a British
company, the developer of the eMAR traceability solution for
prescription drugs prepared in pill dispensers for use in
pharmacies and nursing homes;
- I-MEDS, a German
wholesaler and distributor of equipment and accessories for
supplying drugs to patients and pharmacies.
These different operations will help Equasens
Group accelerate its expansion and reinforce its presence in
several European countries. In particular:
- in the United
Kingdom, by combining CAREMEDS' eMAR medication traceability
solution with MALTA INFORMATIQUE's TITANLINK facility management
solution (MALTA intends to replicate its business model, based on
the successful example of MALTA BELGIUM in Belgium);
- in Germany, by
enhancing MULTIMEDS’ manual dispensing range with the Group's
pharmacy automation solutions, and in particular the addition of
AUTOMEDS' semi-automatic dispensing systems, which are perfectly
suited to the German market in terms of design and capacity.
Equasens Group’s
value-added differentiation has been reinforced by the recent
qualification of its software offerings for inclusion in the Ségur
programme, solidifying its position on the cutting edge of its
market as key contributor to and leader in the healthcare
ecosystem.
With a net cash
position (net of all loans) of €45.45m, Equasens Group maintains a
high degree of autonomy and a significant investment capacity to
take advantage of future acquisition opportunities.
Equasens Group remains
confident and confirms its targets for growth and profitability in
2022, in view of the non-recurring nature of the expenses of the
first half.
Financial
calendar:
- Publication of Q3 2022
revenue: 9 November 2022 (after the close of trading).
- Publication of FY 2022 annual
sales: 3 February 2023 (after the close of trading).
About Equasens
Group:
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group is
currently developing the leading healthcare platform and a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment
and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP -
GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker
Code: EQS
For all the latest news on Equasens Group go to
www.equasens.com
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Jean-Yves SAMSONTel. +33 (0) 83 15 90 67 -
jean-yves.samson@equasens.com
Media Relations:
FIN’EXTENSO - Isabelle APRILE
Tel. +33 (0)1 39
97 61 22 - i.aprile@finextenso.fr
1 “Ségur referencement”: a mechanism enabling
qualifying software developers to apply for funding under the
French “Ségur” digital health investment programme.
- EQUASENS_PRESSRELEASE_20220922_RN S1 2022_en_US
Equasens (EU:EQS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Equasens (EU:EQS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024